

Beiqing Pan

Telephone: 646-483-1836
E-mail: panbq@yahoo.com

EDUCATION

8/2004	Ph.D. Medicine	Department of Medicine, The University of Adelaide, Adelaide, Australia <u>Thesis title:</u> Mechanisms of skeletal disease mediated by haematological malignancies
5/2002	M.Sc., Medical Science	Department of Medicine, The University of Adelaide, Adelaide, Australia <u>Thesis title:</u> Molecular and cellular studies of zoledronic acid-A potent inhibitor of multiple myeloma-induced osteolysis
7/1994	M.D.	Zhejiang Medical University, Hangzhou, China

EXPERIENCE

9/2013-present	Hematologist/ Medical Oncologist	Regional cancer care associates, LLC-Somerset division
7/2010-6/2013	Fellow	Hematology/Oncology, Columbia University, New York, U.S.A.
7/2007-6/2010	Resident	Medicine, New York Downtown Hospital, New York, U.S.A.
8/2004-6/2007	Post-doctoral fellow	Hematology, Mount Sinai School of Medicine, New York, U.S.A.
8/1997-4/2000	Fellow	Hematology, Sir Run Run Shaw Hospital, Hangzhou, China
8/1994-7/1997	Resident	Internal Medicine, Sir Run Run Shaw Hospital, Hangzhou, China

AWARDS

2006	ASH annual meeting travel award
2002-2004	International postgraduate research scholarships (IPRS) The University of Adelaide Scholarship, Adelaide, Australia

QUALIFICATIONS/CERTIFICATIONS

USMLE Scores:	Step 1: 243/98 (Dec. 2005)	Step 2CK: 237/96 (Aug. 2006)
	Step 2CS: pass (May, 2006)	Step 3: 230/95 (Jan. 2007)
ECFMG certified (Sept. 18, 2006)		
Internal Medicine Board Certified (Aug 16, 2010)		

CLINICAL SKILLS

Bone Marrow aspiration and biopsy, Thoracentesis, Paracentesis, Lumbar puncture, Intrathecal Injection, central line and A line placement, arthrocentesis and other medical procedures

GRANT

Generation and Hematopoietic Differentiation of Fanconi Anemia Human Embryonic Stem Cells, Fanconi Anemia Research Fund, 2006-2007

MEMBERSHIPS

American Society of Hematology, American Society of Clinical Oncology

NATIONALITY U.S. citizen

LANGUAGES Fluent in Mandarin and English

PUBLICATIONS

1. Deng C, Pan B, O'Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013 Jan 1;19(1):22-7. Epub 2012 Nov 15.
2. Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther. 2012 Oct;136(1):56-68. Epub 2012 Jul 14.
3. Pan B, Lee Y, Rodriguez T, Lee J, Saif MW. Secondary tumors of the pancreas: a case series. Anticancer Res. 2012 Apr;32(4):1449-52.
4. Tsangari H, Findlay DM, Zannettino ACW, Pan B, Kuliwaba JS, Fazzalari NI. Evidence for reduced bone formation surface relative to bone resorption surface in female femoral fragility fracture patients. Bone. 2006 Dec; 39 (6): 1226-35.
5. Pan B, Farrugia NA, To LB, Green J, Lynch K, Findlay MD, Zannettino ACW. The Nitrogen-Containing Bisphosphonate, Zoledronic Acid, Influences RANKL Expression in Human Osteoblast-Like Cells by Activating TNF-alpha Converting Enzyme (TACE). J Bone Miner Res. 2004 Jan; 19(1):147-154.
6. Pan B, To LB, Farrugia NA, Findlay MD, Green J, Evdokiou A, Lynch K, Atkins JG, Zannettino ACW. The Nitrogen-Containing Bisphosphonate, Zoledronic Acid Increases Mineralization of Human Bone-Derived Cells *in vitro*. Bone. 2004 Jan;34(1):112-23.
7. Zannettino ACW, Pan B, Farrugia NA, Atkins JG, To LB. Identification and Clinical Relevance of Receptor Activator of Nuclear Factor κ B Ligand Expression of Myeloma Cells. Reply. Cancer Research. 2004 Jan; 64 (2): 773-775.
8. Farrugia NA, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino ACW. RANKL Expression by Human Myeloma Cells Mediates Osteoclast Formation *in vitro* and Correlates with Bone Destruction *in vivo*. Cancer Research. 2003 Sept; 63(17):5438-5445.
9. Atkins GJ, Kostakis P, Pan B, Farrugia A, Gronthos S, Evdokiou A, Harrison K, Findlay DM, Zannettino AC. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res. 2003 Jun;18(6):1088-98.
10. Zhang J, Pan H, Huang J, Wang Y, Pan B. A Clinical Study of VID Regimen in Treatment for Relapsed or Refractory Lymphoma. Journal of Zhejiang Oncology. Vol.5 No.3, 1999:147-148
11. Pan B, Huang J, Wang Y, Zhang J. A case report of Primary Extramedullary Leukemia. Journal of Clinical Hematology. Vol.12, suppl. 1999: 107-108
12. Pan B, Huang J. Biphosphonate application in multiple myeloma (review). Overseas medicine: Hematology and transfusion fascicle Vol 22 No.4, 1999: 214-217
13. Huang J, Wang Y, Pan B, Zhang J. A case report of Cladribine in treatment of hairy cell leukemia following failure treatment of α -interferon. Journal of Practical Oncology. Vol.13 No.4 1998:250-151
14. Huang J, Pan B, Wang Y, Zhang J. Prophylactic single-donor platelet transfusion in thrombocytopenia. Zhejiang Medicine, Vol 20, No.9, 1998: 516-518

my 11/25/13

CONFERENCE PRESENTATIONS

1. Dang C, Lin N, Moy B, Come S, Lake D, Theodoulou M, Troso-Sandoval T, Dickler M, Gorsky M, D'Andrea G, Modi S, Seidman A, Drullinsky P, Partridge A, Schapira L, Wulf G, Gilewski T, Atieh D, Mayer E, Isakoff S, Sugarman S, Fornier M, Traina T, Bromberg J, Currie V, Robson M, Burstein H, Overmoyer B, Ryan P, Kuter I, Younger J, Schumer S, Tung N, Zarwan C, Schipper L, Godfrey L, Gantman K, Hallisey M, Kasper H, Pan B, Morris P, Chen C, Patil S, Winer E, Norton L, Hudis C. Dose-Dense (DD) Doxorubicin and Cyclophosphamide (AC) followed by weekly Paclitaxel (P) with Trastuzumab (P) and Lapatinib (L) in HER2/neu Overexpressed/Amplified Breast Cancer (BCA): First Safety Results. 44th American Society of Clinical Oncology annual meeting, May 30-June 3, 2008
2. Pan B, Kennedy M, Keller G, Najfeld V, Walsh CW. Knockdown of the Fanconi Anemia Gene FANCD2 Directly Affects Hematopoiesis in Human Embryonic Stem Cells. The American Society of Hematology 48th Annual Meeting. Orlando, Florida, December 9-12, 2006.
3. Pan B, Kennedy M, Keller G, Najfeld V, Walsh CW. Generation of Fanconi Anemia Phenotype using Human Embryonic Stem Cells. Eighteenth Annual International Fanconi Anemia Scientific Symposium. Bethesda, October 19-22, 2006. (Oral presentation)
4. Pan B, Walsh CW. Genetic conversion of human embryonic stem cells to Fanconi anemia phenotype. International Society for Stem Cell Research 4th Annual Meeting. Toronto, June 29-July 2, 2006.
5. Pan B, Walsh CW. Human embryonic stem cells: genetic conversion to the Fanconi anemia phenotype. American Society of Gene Therapy 9th Annual Meeting. Baltimore, May 31-June 4, 2006.
6. Pan B, To LB, Farrugia NA, Kostakis P, Atkins GJ, Zannettino ACW. Multiple Myeloma-Derived Pro-Inflammatory Cytokines Enhance Osteoclastogenesis by Increasing the Number of RANKL-Expressing STRO-1 Positive Osteoprogenitor Cells. American Society of Haematology 45th annual meeting, San Diego, U.S.A. December 2003.
7. Farrugia NA, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, Findlay DM, Bardy P, Zannettino ACW. RANKL Expression by Human Myeloma Cells Mediates Osteoclast Formation In Vitro and Correlates With Bone Destruction In Vivo. IX Int Workshop on MM, Salamanca, Spain, May 2003.
8. Pan B, To LB, Findlay MD, Farrugia NA, Evdokiou A, Atkins JG, Zannettino ACW. The Nitrogen-Containing Bisphosphonate, Zoledronic Acid Increases Mineralization of Human Bone-Derived Cells in vitro. IX Int Workshop on MM, Salamanca, Spain, May 2003.
9. Pan B, Farrugia NA, To LB, Zannettino ACW. The Nitrogen-Containing Bisphosphonate, Zoledronic Acid Regulates RANKL Expression in Human Osteoblast-Like Cells, by Activating TNF-alpha Converting Enzyme (TACE). IX Int Workshop on MM, Salamanca, Spain, May 2003.
10. Pan B, Findlay DM, To LB, Evdokiou A, Atkins GJ, Zannettino ACW. Zoledronate is anabolic for human osteoblast-like cells. Haematology society of Australian and New Zealand/ Australasian society of blood transfusion/Australasian Society of thrombosis and haemostasis joint annual scientific meeting, Adelaide, SA, September 2002. (oral presentation)
11. Pan B, To LB, Evdokiou A, Atkins GJ, Findlay DM, Labrinidis A, Bouralexis S, Zannettino ACW. In vitro studies examining the effect of the amino bisphosphonate, zoledronic acid on osteoblast-like cells. "Fracture and bone repair: pushing the boundaries" an international society for fracture repair meeting, Clare, SA, March 2002. (oral presentation)
12. Farrugia A, Atkins GJ, Pan B, To LB, Kostakis P, Bardy P, Horvath N, Findlay DM, Zannettino ACW. RANK ligand (RANKL) is expressed by human myeloma cells: direct support of osteoclast formation and activation by myeloma cells. "Fracture and bone repair: pushing the boundaries" an international society for fracture repair meeting, Clare, SA, March 2002.
13. Pan B, Farrugia A, Atkins GJ, Liapis P, Bardy P, Horvath N, To LB, Zannettino ACW. Osteoclast Differentiation Factor (RANKL/ODF) is a Key Mediator of Multiple Myeloma Cell Proliferation. Hanson symposium, Adelaide, South Australia, November 2000.

mpc 11/25/13